Thursday, June 18, 2020

Engrail Therapeutics Finds $32M

San Diego-based Engrail Therapeutics, a biopharmaceuticals company developing treatments for diseases of the nervous system, has raised $32M in a Series A funding, the company announced this mroning. The funding was led by Nan Fung Life Sciences (NFLS). The company said the funding will go towards clinical development of its first pipeline asset, ENX-101, a sub-type selective GABA A modulator. Vikram Sudarsan, Ph.D. is CEO and President of the new company.